These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 35788237)

  • 1. Efficacy and safety of intravenous daratumumab-based treatments for AL amyloidosis: a systematic review and meta-analysis.
    Sun C; Wang X; Zhang R; Xu L; Wang B; Li J
    Cancer Cell Int; 2022 Jul; 22(1):222. PubMed ID: 35788237
    [TBL] [Abstract][Full Text] [Related]  

  • 2. First report of outcomes in patients with stage IIIb AL amyloidosis treated with Dara-VCD front-line therapy.
    Chakraborty R; Rosenbaum C; Kaur G; Bhutani D; Radhakrishnan J; Mapara MY; Maurer M; Lentzsch S
    Br J Haematol; 2023 Jun; 201(5):913-916. PubMed ID: 36896578
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Efficacy and safety of daratumumab in the treatment of advanced light chain amyloidosis].
    Shen KN; Miao HL; Gao YJ; Cao XX; Zhou DB; Su W; Li J
    Zhonghua Xue Ye Xue Za Zhi; 2022 Jan; 43(1):31-34. PubMed ID: 35231990
    [No Abstract]   [Full Text] [Related]  

  • 4. Clinical Pharmacokinetics and Pharmacodynamics of Daratumumab.
    Kim K; Phelps MA
    Clin Pharmacokinet; 2023 Jun; 62(6):789-806. PubMed ID: 37129750
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Daratumumab Monotherapy in Severe Patients with AL Amyloidosis and Biopsy-Proven Renal Involvement: A Real Life Experience.
    Roccatello D; Fenoglio R; Naretto C; Baldovino S; Sciascia S; Ferro M; Rossi D
    J Clin Med; 2020 Oct; 9(10):. PubMed ID: 33050272
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Daratumumab Plus Bortezomib and Dexamethasone in Newly Diagnosed Systemic Light Chain Amyloidosis.
    Kennedy VE; Natsuhara K; Maringanti SA; Shah ND; Arora S; Wolf J; Martin TG; Aras MA; Chung A; Wong SW
    Curr Probl Cancer; 2023 Jun; 47(3):100953. PubMed ID: 36807996
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA.
    Palladini G; Kastritis E; Maurer MS; Zonder J; Minnema MC; Wechalekar AD; Jaccard A; Lee HC; Bumma N; Kaufman JL; Medvedova E; Kovacsovics T; Rosenzweig M; Sanchorawala V; Qin X; Vasey SY; Weiss BM; Vermeulen J; Merlini G; Comenzo RL
    Blood; 2020 Jul; 136(1):71-80. PubMed ID: 32244252
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical efficacy of daratumumab, pomalidomide, and dexamethasone in patients with relapsed or refractory myeloma: Utility of re-treatment with daratumumab among refractory patients.
    Nooka AK; Joseph NS; Kaufman JL; Heffner LT; Gupta VA; Gleason C; Boise LH; Lonial S
    Cancer; 2019 Sep; 125(17):2991-3000. PubMed ID: 31090928
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Subcutaneous daratumumab in Asian patients with heavily pretreated multiple myeloma: subgroup analyses of the noninferiority, phase 3 COLUMBA study.
    Iida S; Ishikawa T; Min CK; Kim K; Yeh SP; Usmani SZ; Mateos MV; Nahi H; Heuck C; Qin X; Parasrampuria DA; Gries KS; Qi M; Bahlis N; Ito S
    Ann Hematol; 2021 Apr; 100(4):1065-1077. PubMed ID: 33599794
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and Safety of Daratumumab-based Regimens in Pretreated Light Chain (AL) Amyloidosis: A Systematic Review.
    Ehsan H; Rafae A; Masood A; Wahab A; Sana MK; Ansar I; Neupane K; Umar A; Ehsan A; Hashmi H
    Clin Lymphoma Myeloma Leuk; 2022 May; 22(5):e285-e292. PubMed ID: 34879994
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Final analysis of the phase III non-inferiority COLUMBA study of subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma.
    Usmani SZ; Nahi H; Legiec W; Grosicki S; Vorobyev V; Spicka I; Hungria V; Korenkova S; Bahlis NJ; Flogegard M; Bladé J; Moreau P; Kaiser M; Iida S; Laubach J; Magen H; Cavo M; Hulin C; White D; De Stefano V; Lantz K; O'Rourke L; Heuck C; Delioukina M; Qin X; Nnane I; Qi M; Mateos MV
    Haematologica; 2022 Oct; 107(10):2408-2417. PubMed ID: 35354247
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Daratumumab for relapsed AL amyloidosis-When cumulative real-world data precedes clinical trials: A multisite study and systematic literature review.
    Shragai T; Gatt M; Lavie N; Vaxman I; Tadmor T; Rouvio O; Zektser M; Horowitz N; Magen H; Ballan M; Suru C; Luttwak E; Levi S; Ziv-Baran T; Avivi I; Cohen YC
    Eur J Haematol; 2021 Feb; 106(2):184-195. PubMed ID: 33090552
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety, tolerability, and response rates of daratumumab in relapsed AL amyloidosis: results of a phase 2 study.
    Sanchorawala V; Sarosiek S; Schulman A; Mistark M; Migre ME; Cruz R; Sloan JM; Brauneis D; Shelton AC
    Blood; 2020 Apr; 135(18):1541-1547. PubMed ID: 31978210
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Switching to daratumumab SC from IV is safe and preferred by patients with multiple myeloma.
    Mateos MV; Rigaudeau S; Basu S; Spicka I; Schots R; Wrobel T; Cook G; Beksac M; Gries KS; Kudva A; Tromp B; Van Rampelbergh R; Pei H; Wroblewski S; Carson R; Delioukina M; White D
    J Oncol Pharm Pract; 2023 Jul; 29(5):1172-1177. PubMed ID: 36067063
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Daratumumab for the treatment of primary systemic amyloidosis: a multicenter retrospective analysis].
    Liu Y; Huang XH; Duan WB; Fang BJ; Huang DP; Zhang YH; Xu L; Zhang HY; Zhang H; Wen L; Huang XJ; Lu J
    Zhonghua Nei Ke Za Zhi; 2021 Nov; 60(11):987-992. PubMed ID: 34689520
    [No Abstract]   [Full Text] [Related]  

  • 17. Daratumumab therapy for relapsed or refractory multiple myeloma: a single-center retrospective study.
    Sunami K; Murakami H; Tagashira H; Ueda H; Moriyama T; Ishikawa T; Yoshioka T; Makita M
    Int J Clin Oncol; 2020 Dec; 25(12):2151-2157. PubMed ID: 32715356
    [TBL] [Abstract][Full Text] [Related]  

  • 18. First-line daratumumab shows high efficacy and tolerability even in advanced AL amyloidosis: the real-world experience.
    Jeryczynski G; Antlanger M; Duca F; Binder-Rodriguez C; Reiter T; Simonitsch-Klupp I; Bonderman D; Kain R; Krauth MT; Agis H
    ESMO Open; 2021 Apr; 6(2):100065. PubMed ID: 33667762
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of Daratumumab-Based Regimens Compared to Standard of Care in Transplant-Eligible Multiple Myeloma: A Meta-Analysis.
    Menon T; Kataria S; Adhikari R; Khan H; Khalid MZ; Saeeduddin MO; Taj S; Rehman U; Tekin A; Singh R
    Cureus; 2021 May; 13(5):e15098. PubMed ID: 34155463
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis.
    Kastritis E; Palladini G; Minnema MC; Wechalekar AD; Jaccard A; Lee HC; Sanchorawala V; Gibbs S; Mollee P; Venner CP; Lu J; Schönland S; Gatt ME; Suzuki K; Kim K; Cibeira MT; Beksac M; Libby E; Valent J; Hungria V; Wong SW; Rosenzweig M; Bumma N; Huart A; Dimopoulos MA; Bhutani D; Waxman AJ; Goodman SA; Zonder JA; Lam S; Song K; Hansen T; Manier S; Roeloffzen W; Jamroziak K; Kwok F; Shimazaki C; Kim JS; Crusoe E; Ahmadi T; Tran N; Qin X; Vasey SY; Tromp B; Schecter JM; Weiss BM; Zhuang SH; Vermeulen J; Merlini G; Comenzo RL;
    N Engl J Med; 2021 Jul; 385(1):46-58. PubMed ID: 34192431
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.